Statute Details
- Title: Health Products (Therapeutic Products) Regulations 2016
- Act Code: HPA2007-S329-2016
- Type: Subsidiary legislation (SL)
- Status: Current version (as at 27 Mar 2026)
- Enacting Act: Health Products Act (HPA) 2007
- Primary subject: Regulation of manufacture, import, supply, presentation, and registration of therapeutic products in Singapore
- Commencement: (Not provided in the extract)
- Key structure: Parts 1–9, including licensing, supply controls, product presentation, registration, duties/obligations, and exceptions
- Key provisions (from extract): Regulation 2 (definitions); Regulation 3 (scope); Part 2 (licensing for manufacture/import); Part 3 (supply rules); Part 4 (trade descriptions and information); Part 5 (registration and exclusivity); Part 6 (duties and recordkeeping); Part 7–8A (exceptions, including emergency products); Part 9 (certification, quality surveillance, non-compliance, confidentiality)
- Related legislation (as provided): Dental Registration Act 1999; Health Products Act; Healthcare Services Act 2020; Medical Registration Act 1997; Pharmacists Registration Act 2007
What Is This Legislation About?
The Health Products (Therapeutic Products) Regulations 2016 (“Therapeutic Products Regulations”) are Singapore’s detailed regulatory rules for therapeutic products—covering how such products are manufactured, imported, supplied, presented to the public, and registered with the Health Sciences Authority (“Authority”). While the Health Products Act 2007 provides the overarching legal framework, these Regulations operationalise compliance through licensing regimes, product registration requirements, and strict controls on information and labelling.
In practical terms, the Regulations aim to ensure that therapeutic products placed on the Singapore market are safe, of acceptable quality, and supported by accurate regulatory information. They also manage higher-risk categories (notably psychotropic substances and codeine-containing cough preparations) through additional restrictions and recordkeeping. The Regulations further create compliance duties for regulated persons—manufacturers, importers, wholesalers, and registrants—requiring ongoing monitoring, adverse event reporting, and risk management activities.
Finally, the Regulations recognise that not all activities fit neatly within the standard licensing and registration pathways. Accordingly, they provide carefully bounded exceptions (for example, for certain healthcare service licensees, licensed retail pharmacies, named patients, personal imports, and export-only arrangements), including a specific emergency pathway for “emergency therapeutic products”.
What Are the Key Provisions?
1) Definitions and scope (Part 1). The Regulations begin with interpretive provisions (notably Regulation 2) and a scope clause (Regulation 3) that clarifies when the Regulations apply. A key feature of the scope is that the Regulations do not apply to therapeutic products that are “clinical research material” (as indicated in the extract). This matters for practitioners because it delineates the boundary between regulated therapeutic products and research-stage materials—often relevant to licensing, labelling, and registration obligations.
2) Licensing for manufacture and import (Part 2). Part 2 establishes licensing requirements for manufacturers and importers. Regulation 4 sets out requirements for the issue of a manufacturer’s licence, while Regulation 5 does the same for an importer’s licence. These licensing provisions are the gateway controls: without the relevant licence, regulated manufacture or import activities generally cannot be carried out.
Part 2 also includes targeted controls for higher-risk substances. Regulation 6 addresses import of therapeutic products containing psychotropic substances. This is a critical compliance area for companies handling controlled medicines, as it signals that additional conditions and/or documentation requirements apply beyond general import licensing.
3) Supply controls: wholesale and retail, including controlled medicines (Part 3). Part 3 is central to day-to-day market conduct. It contains requirements for supply “for purposes of section 17” (Regulation 7), then divides into wholesale supply (Division 1), retail supply of registered therapeutic products (Division 2), and other supply requirements (Division 3), followed by wholesaler licensing (Division 4).
For wholesale supply, the Regulations include rules on export of psychotropic-substance therapeutic products (Regulation 8), export of codeine cough preparations (Regulation 9), and wholesale of therapeutic products containing “Second Schedule ingredients” (Regulation 10). These provisions reflect that certain ingredients trigger enhanced regulatory scrutiny, likely due to misuse potential or public health considerations.
For retail supply, the Regulations distinguish between medicine categories and supply channels. Regulations 11–13 address supply by retail sale of prescription-only medicine, supply by administration of prescription-only medicine, and supply by retail sale of pharmacy-only medicine. Regulation 14 imposes restrictions on retail supply of codeine cough preparations—again highlighting a controlled category. Regulation 15 addresses supply of “general sale list medicine” by retail sale vending machine, which is particularly relevant for pharmacy operators and retail technology deployments.
Part 3 also imposes operational recordkeeping and dispensing requirements. Regulation 16 requires records of supply of prescribed therapeutic products, and Regulation 17 governs supply by dispensing therapeutic products. These provisions are important for enforcement readiness: they create a paper trail that can be audited and used to investigate complaints, suspected counterfeits, or adverse outcomes.
4) Presentation and information obligations (Part 4). Part 4 focuses on how therapeutic products are presented to the public and what information must accompany them. Regulation 19 addresses “trade descriptions”, while Regulation 20 requires prescribed information to be provided with therapeutic products. Regulation 21 provides corrective measures where there is contravention of trade descriptions or failure to provide prescribed information. For practitioners, this is a key area for regulatory risk: marketing claims, packaging language, and patient-facing information must align with regulatory requirements, and non-compliance can trigger corrective actions.
5) Registration of therapeutic products and patent-related issues (Part 5). Part 5 sets out the registration regime. Regulation 22 provides requirements for registration. Regulation 23 addresses whether a therapeutic product is subject to patent, and Regulation 24 provides for cancellation of registration where there is a patent dispute. Regulation 24A introduces a prescribed time for cancellation of registration for non-payment of a retention fee—an administrative compliance point that can have commercial consequences if missed.
Part 5 also includes provisions on false declarations (Regulation 25), confidentiality of supporting information for innovative therapeutic product applications (Regulation 26), and circumstances where such protection does not apply (Regulation 27). Regulation 28 addresses disclosure of information on applications for registration, and Regulation 29 introduces “registration exclusivity”. This exclusivity concept is particularly relevant to innovators and generic or follow-on product applicants, as it can affect market entry timing and competitive strategy.
6) Ongoing duties: records, reporting, recall, and risk management (Part 6). Part 6 is designed for continuous compliance rather than one-off approvals. Division 1 imposes general duties: a duty to comply with enforcement requirements (Regulation 30), maintain records of manufacture (Regulation 31), maintain records of receipt and supply (Regulation 32), maintain records of defects and adverse effects (Regulation 33), report defects and adverse effects (Regulation 34), and notify the Authority concerning recall (Regulation 35). These provisions align with pharmacovigilance and quality management expectations.
Division 2 then specifies duties for licensees (Regulations 36–38), including a “responsible person” requirement (Regulation 39) and an offence for contravention of duties (Regulation 40). Regulation 41 addresses changes affecting a licence—important for corporate reorganisations, site changes, and changes in key personnel or processes.
Division 3 imposes duties on registrants (Regulations 42–45), including changes concerning registered therapeutic products (Regulation 42), information on validity of data submitted or considered by the Authority (Regulation 43), submission of benefit-risk evaluation reports (Regulation 44), and a duty to carry out a risk management plan (Regulation 45). For practitioners, these provisions are often where regulatory obligations continue long after initial registration—requiring governance systems for post-market surveillance and periodic benefit-risk reassessment.
7) Exceptions and emergency pathway (Part 7 and Part 8A). Part 7 provides exceptions allowing manufacture, import, and wholesale without a licence in defined circumstances. These include compounding at approved permanent premises of specified healthcare service licensees (Regulation 46), transfer by specified healthcare service licensees without wholesaler’s licence (Regulation 47), compounding at licensed retail pharmacies without manufacturer’s licence (Regulation 48), and wholesale supply by holders of pharmacy licences without wholesaler’s licence (Regulation 49). There are also exceptions for named patients (Regulations 50–51), personal imports (Regulation 52), and wholesale for export (Regulation 53), among others.
Part 8 provides exceptions for supply without registration (Regulations 58–60, and Regulation 59 for supply under contractual agreement with a licensed manufacturer, and Regulation 60 for previously registered therapeutic products). Part 8A introduces a specific exception for “emergency therapeutic products” (Regulation 60A) covering manufacture, import, and supply in emergency contexts. This emergency pathway is crucial for hospitals and clinicians when time-sensitive treatment is required, but it also implies that the conditions for invoking the exception must be strictly met.
8) Miscellaneous: certification, quality surveillance, and confidentiality (Part 9). Part 9 includes certification requirements for therapeutic products intended for export (Regulation 61) and certificates of manufacturing and distribution standards (Regulations 62–63). It also covers product quality surveillances (Regulation 65), non-compliant therapeutic products (Regulation 66), and confidentiality of information (Regulation 67). These provisions support international compliance and domestic enforcement, while also protecting commercially sensitive information.
How Is This Legislation Structured?
The Regulations are organised into nine Parts. Part 1 contains preliminary matters (citation, definitions, and scope). Part 2 covers manufacture and import, including licensing and special rules for psychotropic substances. Part 3 governs supply, distinguishing wholesale and retail supply, and includes recordkeeping and dispensing requirements. Part 4 addresses presentation of therapeutic products, focusing on trade descriptions and required information. Part 5 establishes the registration framework, including patent-related cancellation and confidentiality/exclusivity concepts. Part 6 sets out ongoing duties and obligations for licensees and registrants, including recordkeeping, reporting, recall notification, benefit-risk evaluation, and risk management. Part 7 provides exceptions for licence-free manufacture/import/wholesale in specified scenarios. Part 8 provides exceptions for supply without registration, and Part 8A adds an emergency therapeutic product exception. Part 9 contains miscellaneous enforcement-supporting provisions such as certification, quality surveillance, non-compliance handling, and confidentiality.
Who Does This Legislation Apply To?
In general, the Regulations apply to persons involved in the lifecycle of therapeutic products in Singapore: manufacturers, importers, wholesalers, retail suppliers, and registrants of therapeutic products. The licensing and duties framework means that regulated entities must ensure that their operations, documentation, and post-market activities comply with the Regulations.
The scope also extends to specific categories of healthcare service licensees and pharmacy licence holders who may rely on exceptions to conduct certain activities without a licence or without registration, provided the statutory conditions are satisfied. For named patients and personal imports, the Regulations create narrow pathways that permit controlled activities without full licensing/registration, but these pathways are typically fact-specific and require careful compliance with the relevant exception provisions.
Why Is This Legislation Important?
The Therapeutic Products Regulations are important because they operationalise the Health Products Act’s public health objectives through enforceable, detailed requirements. For practitioners, the Regulations are not merely “administrative”: they create compliance duties that affect corporate licensing, product launch timelines, marketing and labelling practices, and ongoing pharmacovigilance obligations.
From an enforcement perspective, the Regulations’ emphasis on records (manufacture, receipt and supply, defects and adverse effects) and reporting (defects/adverse effects and recall notification) means that compliance failures can lead to regulatory action. The presence of offences for contraventions of duties (including contraventions by licensees) further increases the need for robust internal governance, training, and audit readiness.
Commercially, Part 5’s registration, patent-dispute cancellation, retention fee timing, confidentiality protections, and registration exclusivity provisions can materially affect market access and competitive positioning. Practitioners advising innovators, generic applicants, or distributors must therefore treat the Regulations as a core part of product strategy—not only as a compliance checklist.
Related Legislation
- Health Products Act 2007
- Healthcare Services Act 2020
- Medical Registration Act 1997
- Pharmacists Registration Act 2007
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Therapeutic Products) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.